Iconix Biosciences Inc., the leader in toxicogenomics products and services, has pioneered the integration of chemistry and genomics to enable the pharmaceutical and other industries to develop safer drug candidates and compounds. The company’s technologies increase the odds of advancing the right candidates to the clinic, reduce attrition rates in late-stage trials and help keep the costs of drug discovery in check. Iconix provides reference systems and universally recognized expertise to predict safety liabilities, side effects and mechanisms of toxicity for drug candidates and environmental chemicals. Iconix’s DrugMatrix system has been installed at the U.S. Food and Drug Administration for use by CDER (Center for Drug Evaluation and Research) scientists and reviewers in a range of toxicogenomics applications and is used by the FDA to evaluate voluntarily genomic data submissions.
Entelos, Inc. Acquired Iconix Biosciences, Inc. in 2007.
|12/31/06||Series B||6M||Abingworth Management, Institutional Venture Partners, Kleiner Perkins Caufield & Byers, Palladin Group, Bristol-Myers Squibb, Eli Lilly, Incyte, MDS Pharma, Microcide Pharmaceuticals, Motorola Life Science, Motorola Ventures||Unknown|